Abstract
ABSTRACTNotch signaling is crucial for lymphocyte effector and memory differentiation. While tumor suppress Notch signaling in antitumor lymphocytes, recent studies show that the pharmacological Delta-like ligand-1 multivalent cluster or proteasome inhibitor bortezomib can restore Notch–NF-κB signaling in T cells of tumor-bearing hosts with a potential to overcome cancer cell resistance to therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have